Hypermarcas (HYPMY) Stock Price, News & Analysis

Company Overview

Hypermarcas S.A. is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products. Its pharmaceutical lineup includes analgesics, anti-inflammatories, vitamins and dermatological preparations, while its consumer goods segment encompasses shampoos, soaps, lotions and oral hygiene items under multiple local brands.

Primarily focused on the domestic Brazilian market, Hypermarcas has also extended its reach into other Latin American countries via export partnerships and regional distributors. Over the years, the company has grown through acquisitions of smaller domestic drugmakers and consolidation of well-known local brands. Detailed executive leadership information is not widely available in public sources.

Key Stats

• Today's Range: $4.74 to $4.86
• 50-Day Range: $3.92 to $4.81
• 52-Week Range: $3.71 to $5.50
• Volume: 17,202 shs
• Average Volume: 32,661 shs
• Market Capitalization: $3.39 billion
• P/E Ratio: 10.02
• Dividend Yield: 2.70%
• Price Target: N/A
• Consensus Rating: Buy

Hypermarcas Stock Analysis - MarketRank™

Hypermarcas scored higher than 84% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Buy

Consensus Rating

Hypermarcas has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Hypermarcas has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 28.30%

Earnings Growth

Earnings for Hypermarcas are expected to grow by 28.30% in the coming year, from $0.53 to $0.68 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hypermarcas is 10.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hypermarcas is 10.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.24.

Price to Book Value per Share Ratio

Hypermarcas has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Hypermarcas has been sold short.

Short Interest Ratio / Days to Cover

Hypermarcas has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hypermarcas has recently decreased by 99.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Hypermarcas pays a meaningful dividend of 2.70%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Hypermarcas does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Hypermarcas is 27.08%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Hypermarcas will have a dividend payout ratio of 19.12% next year. This indicates that Hypermarcas will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.90

News Sentiment

Hypermarcas has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Hypermarcas this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hypermarcas insiders have not sold or bought any company stock.

Percentage Held by Institutions

Hypermarcas has minimal institutional ownership at this time.

HYPMY Stock Analysis - Frequently Asked Questions

How have HYPMY shares performed this year?

Hypermarcas' stock was trading at $4.1375 on January 1st, 2026. Since then, HYPMY stock has increased by 16.3% and is now trading at $4.81.

How were Hypermarcas' earnings last quarter?

Hypermarcas (OTCMKTS:HYPMY) released its quarterly earnings results on Wednesday, April, 29th. The company reported $0.10 earnings per share for the quarter. The company had revenue of $383.13 million for the quarter. Hypermarcas had a trailing twelve-month return on equity of 14.08% and a net margin of 19.41%.

How do I buy shares of Hypermarcas?

Shares of HYPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 4/29/2026
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HYPMY
• CIK: 1486749
• Web: www.hyperapharma.com.br
• Phone: 55-11-3627-4206
• Fax: N/A
• Employees: 10,481
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): $0.48
• Trailing P/E Ratio: 10.02
• Forward P/E Ratio: 9.08
• P/E Growth: N/A
• Net Income: $213.10 million
• Net Margins: 19.41%
• Pretax Margin: 4.04%
• Return on Equity: 14.08%
• Return on Assets: 6.91%

Debt

• Debt-to-Equity Ratio: 0.61
• Current Ratio: 1.27
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $1.38 billion
• Price / Sales: 2.46
• Cash Flow: $0.49 per share
• Price / Cash Flow: 9.81
• Book Value: $3.54 per share
• Price / Book: 1.36

Miscellaneous

• Outstanding Shares: 704,010,000
• Free Float: N/A
• Market Cap: $3.39 billion
• Optionable: Not Optionable
• Beta: 0.73